NCT05945823 2025-12-29Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsTaiho Oncology, Inc.Phase 2 Active not recruiting53 enrolled
NCT03784014 2025-12-11MULTISARCInstitut National de la Santé Et de la Recherche Médicale, FrancePhase 3 Active not recruiting603 enrolled